Ir al contenido principal

Episodio 8. Simulando tofacitinib versus adalimumab. Datos de vida real potenciados.

Imagen
By Dr Juan Gulin

 Episodio 8. Simulando tofacitinib versus adalimumab. Datos de vida real potenciados.

La base de datos OPAL de Australia es una verdadera joya. Comentamos un "ensayo clinico simulado" utilizando los pacientes con AR y sus HCEs comparando tofacitinib versus adalimumab y comparamos con recomendaciones EULAR y datos de un ECA de 2017.

Deakin CT, De Stavola BL, Littlejohn G, et al. Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia. JAMA Netw Open. 2023;6(6):e2320851. doi:10.1001/jamanetworkopen.2023.20851

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806589

Littlejohn  GO, Tymms  KE, Smith  T, Griffiths  HT.  Using big data from real-world Australian rheumatology encounters to enhance clinical care and research.   Clin Exp Rheumatol. 2020;38(5):874-880. https://pubmed.ncbi.nlm.nih.gov/31820719/

 Fleischmann  R, Mysler  E, Hall  S,  et al; ORAL Strategy Investigators.  Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.   Lancet. 2017;390(10093):457-468. doi:10.1016/S0140-6736(17)31618-5  

Entradas populares de este blog

Episodio 19: Primer sintoma de espondilitis

By Dr Juan Gulin
Episodio 19: Primer sintoma de espondilitis Investigadores españoles y mexicanos examinan las cohortes RESPONGISER y RESPONDIA en pos de establecer los primeros sintomas y signos de las distintas espondiloartropatias Puche-Larrubia MÁ, Ladehesa-Pineda L, Vázquez-Mellado J, et al. Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries. RMD Open 2023;9:e003235. doi: 10.1136/ rmdopen-2023-003235 E. Collantes, P. Zarco, E. Muñoz, X. Juanola, J. Mulero, J. L. Fernández-Sueiro, J. C. Torre-Alonso, J. Gratacós, C. González, E. Batlle, P. Fernández, L. F. Linares, E. Brito, L. Carmona, Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER)—extended report, Rheumatology , Volume 46, Issue 8, August 2007, Pages 1309–1315, https://doi.org/10.1093/rheumatology/kem084   Janitzia Vázquez-Mellado a , P...
Read more »

Episodio 5. Guias y vagos

By Dr Juan Gulin
 Episodio 5. Guias y vagos.  https://pod.link/1688456486 OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS. https://ard.bmj.com/content/82/Suppl_1/154   Research Update: Using Vagus Nerve Stimulation for Rheumatic Disease. April 8, 2023 • By Mary Beth Nierengarten . https://www.the-rheumatologist.org/article/research-update-using-vagus-nerve-stimulation-for-rheumatic-disease/ ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. https://clinicaltrials.gov/
Read more »